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Abstract 
Recommendations and guidelines for the collection, generation, source and usage of utility data for 
Health Technology Assessment (HTA) vary across different countries, with no international 
consensus. Many international agencies generate their own guidelines providing details on their 
preferred methods for HTA submissions, and there is variability in both what they recommend and 
the clarity and amount of detail provided in their guidelines. This article provides an overview of 
international regulations and recommendations for utility data in HTA for a selection of key HTA 
countries: Australia, Canada, France, Germany, The Netherlands, Spain (Catalonia), Sweden and UK 
(England and Wales, Scotland). 
The article finds that international guidelines are typically clear and detailed for the selection of 
countries assessed regarding the source description of health states (for example generic 
preference-based measure) and who should provide preference-weights for these health states (for 
example general population for own country). Many guidelines specify the use of off-the-shelf 
generic preference-based measures, and some further specify a measure, such as EQ-5D. However 
international guidelines are either unclear or lack detailed guidance regarding the collection (for 
example patients report own health), source (for example clinical trial) and usage (for example 
adjusting for comorbidities) of utility values.  
It is argued that there is a need for transparent and detailed international guidelines on utility data 
recommendations to provide the best possible evidence to decision-makers. Where this is not 
possible it is recommended that best practice should be used to inform the collection, source and 
usage of utility values in HTA. 
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KEY POINTS FOR DECISION MAKERS 
x There is no international consensus on guidelines for the collection, generation, source and 
usage of utility data for health technology assessment. 
x Individual country recommendations regarding the generation of utility data are typically 
clear and detailed for the key countries assessed regarding a) the source description of 
health states e.g. generic preference-based measure and b) who should provide utility 
values for these health states e.g. general population for own country. 
x Individual country recommendations are unclear or not stated regarding a) who should 
complete the questionnaire, b) the source e.g. clinical effectiveness trial and c) 
methodological options when using utility data in the economic model e.g. adjusting the 
baseline for age. 
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1.  Introduction 
There is no international consensus on guidelines for the use of utility data for health technology 
assessment (HTA) and many international agencies generate their own guidelines providing details 
on their preferred methods for HTA submissions. This has implications for research and trial design. 
This paper provides an overview on international HTA guidelines for key HTA countries (n = 9) pre-
selected as representative settings by the authors: Australia (Pharmaceutical Benefits Advisory 
Committee (PBAC) [1]), Canada (Canadian Agency for Drugs and Technologies in Health (CADTH) [2]), 
France (Haute Autorité de Santé (HAS) [3]), Germany (German National Institute for Quality and 
Efficiency in Health Care (IQWiG) [4]), The Netherlands (College voor zorgverzekeringen (CVZ) [5]; 
Busschbach et al[6]), Spain (Catalonia) (CatSalut [7]), Sweden (Pharmaceutical Benefits Board [8]), 
and the United Kingdom (UK) for England and Wales (National Institute of Health and Care 
Excellence (NICE) [9]) and Scotland (Scottish Medicines Consortium (SMC) [10]). This list is not 
exhaustive and does not reflect all international guidance, in particular it focuses upon Western 
Europe, Australia and Canada, and does not include guidance for Africa, Asia, Latin America and 
Eastern Europe. Furthermore this does not include guidance from groups such as the Washington 
Panel [11] or ISPOR [12] which produce comprehensive guidance on best practice for HTA. This 
paper summarises these guidelines for the collection, generation, source and usage of utility data for 
HTA submissions, and provides definitions of the concepts involved. Additional detailed information 
included in the guidelines are provided in the accompanying online supplementary material. 
 
Ŷ ŝŵƉŽƌƚĂŶƚ ƉŽŝŶƚ ŽĨ ĐůĂƌŝĨŝĐĂƚŝŽŶ ŝƐ ƚŚĂƚ ŝƐƐƵĞƐ ĐĂŶ ĞŝƚŚĞƌ ďĞ  ?ŶŽƚ ƐƚĂƚĞĚ ? ?  ?ƌĞĐŽŵŵĞŶĚĞĚ ? Žƌ
 ?ƌĞƋƵŝƌĞĚ ? ?EŽƚƐƚĂƚĞĚŵĞĂŶƐƚŚĂƚƚŚĞƌĞŝƐŶŽŐƵŝĚĂŶĐĞĞǆƉůŝĐŝƚŝŶƚŚĞŵĞƚŚŽĚƐŐƵŝĚĞůŝŶĞƐĨŽƌĂŐŝǀĞŶ
country. Recommended or preferred suggests that the agency in the country would prefer the 
method, but it is implicit that they are open to considering alternative methods if appropriately 
justified, though how open they are may depend on the exact issue and agency. Required states a 
strong preference where the agency may reject HTA submissions not meeting the requirements, and 
this means that there are few requirements specified within the guidelines. 
 
1 Summary of international recommendations for economic evaluation for a selection of 
countries 
Table 1 provides a summary of the economic evaluation methods that are recommended by each of 
the international guidelines.  
 
1.1 Cost-utility analysis 
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For all guidelines cost-utility analysis, where effectiveness is measured using quality adjusted life 
years (QALYs), is the preferred form of economic evaluation with the exception of Germany.  
 
1.2 Perspective 
Guidelines for Canada, Germany, Scotland, Spain, and England and Wales recommend a health 
service perspective which includes costs incurred by the health service in the economic evaluation. 
Guidelines for France, The Netherlands and Sweden recommend a societal perspective which 
includes wider societal costs in addition to costs incurred by the health service in the economic 
evaluation, for example productivity costs, or informal care costs, costs incurred by patient and or 
carer/family (the exact inclusions can vary by country). Whilst Australian guidelines recommend a 
societal perspective in the guidelines it is extremely rare that Australian submissions take this 
perspective. The choice of perspective is important, as this determines which costs and benefits can 
be included in the economic evaluation, and this can impact on the cost-effectiveness results. 
 
1.3 QALY weighting 
The standard approach is to assume that a QALY gained is of equal value regardless of who gains 
that QALY, meaning that all QALYs are given the same QALY weight of 1. With the exception of the 
Netherlands 2015 guidance only available in Dutch (see [13] for further details in English on the 
Netherlands guidance), all guidelines recommend equal QALY weighting, either explicitly or implicitly 
through not specifying any QALY weighting considerations. This means that a QALY is given a 
weighting of 1 and is of equal worth for every recipient, regardless of their characteristics such as 
age, for example age 10 or 80.  
 
However, an alternative approach is to use QALY weighting where a higher (or lower) weight is given 
to QALYs gained by certain patients, for example those who are at the end of their life. The 
Netherlands 2015 guidance refers to different thresholds depending on the necessity of the 
intervention. Australian guidelines state that equity issues can be outlined where these are 
important and relevant. England and Wales guidelines state that a higher QALY weight may be given 
for life-extending treatments provided to patients at the end of their life where life expectancy is 
short (normally less than 24 months), treatment offers an additional 3 or more months and the 
target population is small. The HSUVs themselves remain unaltered, but in effect face a different 
threshold which can mean they are funded although they would not be considered cost effective 
using the standard guidelines. For example, in England and Wales guidelines cancer treatments for 
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end of life patients or orphan drugs may be  funded despite having a cost-per-QALY value greater 
than the standard cost-effectiveness threshold used. 
 
1.4 Carer utility values 
Carer utility values reflect the health-related quality of life of the carer (rather than the patient). 
These can be considered important for economic evaluation of diseases with large carer input and 
where the intervention can impact on the health-related quality of life of the carer. Guidelines for 
Canada, Germany, Scotland and the Netherlands 2015 guidelines state that carer utility values (i.e. 
the utility of the carer of the recipient of the intervention), can be included if relevant, although this 
is typically to be considered separately rather than in the base case analysis (Table 1). England and 
tĂůĞƐŐƵŝĚĞůŝŶĞƐƐƚĂƚĞƚŚĂƚĐĂƌĞƌƐ ?ƵƚŝůŝƚǇǀĂůƵĞƐƐŚŽƵůĚďĞŝŶĐůƵĚĞĚŝŶƚŚĞďĂƐĞĐĂƐĞǁŚĞŶƌĞůĞǀĂŶƚ ?
dŚĞ ƌĞŵĂŝŶŝŶŐ ŐƵŝĚĞůŝŶĞƐ ĚŽ ŶŽƚ ƌĞĨĞƌ ƚŽ ĐĂƌĞƌƐ ? ƵƚŝůŝƚŝĞƐ ? Carer measures include the CarerQol 
[14,15] and the Carer Experience Scale [16] though neither are anchored on the 1-0 full health to 
dead scale required for QALYs. 
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Table 1  International recommendations for economic evaluation  
Country Producing Body Year CUA is 
preferred form 
of economic 
evaluation 
Recommended 
perspective 
Equity considerations for QALY 
weighting 
Carer utility values 
Australia PBAC [1] 2013 Yes Societal (though 
uses non-standard 
definition) 
Equal QALY weighting. Equity 
issues outlined where important 
and relevant 
Not mentioned 
Canada CADTH [2] 2006 Yes Publicly funded 
health care system 
Equal QALY weighting If relevant report 
separately  
France HAS [3] 2012 Yes Societal Equal QALY weighting Not mentioned 
Germany IQWiG [4] 2015 No Health care. 
Optional 
perspectives are 
social insurance and 
societal 
Not mentioned If relevant carer 
consequences can 
be considered 
The 
Netherlands 
CVZ [5,6] 2006 Yes Societal Different thresholds depending on 
the necessity of the intervention in 
2015 guidance in Dutch 
Not mentioned 
Spain 
(Catalonia) 
CatSalut [7] 2014 Yes Catalan Health 
Service. Societal 
may be provided 
separately 
Equal QALY weighting Not mentioned 
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Country Producing Body Year CUA is 
preferred form 
of economic 
evaluation 
Recommended 
perspective 
Equity considerations for QALY 
weighting 
Carer utility values 
Sweden Pharmaceutical 
Benefits Board [8] 
2003 Yes or CEA Societal Not mentioned Not mentioned 
UK: England 
and Wales 
NICE [9] 2013 Yes  NHS and PSS Equal QALY weighting. QALY 
weighting acceptable for life-
extending treatment at end of life 
for patients with short life 
expectancy and small patient 
populations 
All direct health 
effects should be 
included for 
patients or, when 
relevant, carers 
UK: 
Scotland 
SMC [10] 2016 Yes  NHS in Scotland and 
social work 
 Equal QALY weighting Not included in 
reference case, if 
relevant report 
separately 
Key: CADTH  W Canadian Agency for Drugs and Technologies in Health; CEA  W cost effectiveness analysis; CUA  W Cost utility analysis; CVZ - College voor 
zorgverzekeringen; HAS  W Haute Autorité de Santé; IQWiG - German national institute for quality and efficiency in health care; NHS  W National Health 
Service; NICE  W National Institute for Health and Care Excellence; PBAC - Pharmaceutical Benefits Advisory Committee; PSS  W Personal Social Services; SMC  W 
Scottish Medicines Consortium.  
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2 Overview of international recommendations for utility data  
Table 2 provides a summary of the alternative methods that are recommended by each of the 
international guidelines to produce health state utility values (HSUVs) ?ĂƐƚŚĞƐĞĨŽƌŵƚŚĞ ?Y ?ƋƵĂůŝƚǇ
adjustment weight of the QALY, i.e. the utility values anchored on the 1-0 full health-dead QALY 
scale required to generate QALYs. 
 
2.1 Preferred method for generating HSUVs 
2.1.1 Generic preference-based measures 
A generic preference-ďĂƐĞĚŵĞĂƐƵƌĞ ?ŐĞŶĞƌŝĐWD ?ŝƐĂŶ ?ŽĨĨƚŚĞƐŚĞůĨ ?ŵĞĂƐƵƌĞwhich classifies each 
patient to a health state which has a corresponding utility value obtained from an existing set of 
preference weights typically obtained from a representative sample of the general population. Most 
guidelines included in the review recommend the use of an existing PBM to generate HSUVs, and 
some further specify a measure, for example Scotland and England and Wales recommend EQ-5D, 
the Netherlands recommend EQ-5D-5L and Spain (Catalonia) recommend either EQ-5D or SF-6D. The 
main advantage of using the same standardized PBM for all HTA submissions for a particular country 
is that it enables comparability across all interventions, providing consistency in the resource 
allocation process. In addition their performance across a wide range of conditions is well 
established and psychometric properties well known [17].  
 
2.1.2 Condition-specific preference-based measures 
A condition-specific preference-based measure (CSPBM) is a measure of health-related quality of life 
that is specific to a certain condition or disease and that also has an off-the-shelf set of preference 
weights that enables HSUVs to be generated from responses to the measure. None of the guidelines 
recommended condition-specific preference-based measures as the preferred method for 
generating HSUVs. This is most likely because they do not enable comparability across different 
interventions in different conditions, presenting a challenge for consistency in resource allocation 
decisions across all interventions and conditions [18]. 
 
2.1.3 Vignettes 
Vignettes (also referred to as scenario-based utility valuations) are bespoke descriptions of a small 
number of health states specific to the states used in the economic model, typically the descriptions 
of health states are generated by interviews with clinicians or patients [18]. Only Australian 
guidelines state that they accept HSUVs elicited using vignettes to provide the health state 
description (though this is not their preferred technique and it is expected that the values would be 
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scrutinised). One advantage of vignettes is that they can be tailored to suit the economic model and 
can be flexible in terms of what is included in their description. However, vignettes are not regarded 
favourably by the international agencies as they are not comparable across different interventions 
or patient groups. Furthermore they do not reflect the variability of outcomes experienced by 
patients in clinical trials [19]. In addition their construction can be subjective and hence they can be 
prone to inaccurate valuations due to focussing effects as respondents valuing the health states are 
likely to focus on what exactly is described in the health state, yet what is described in the state may 
not be an accurate description.  
 
2.1.4 Direct utility elicitation 
Direct utility elicitation is where patients are asked to directly value their own health using an 
elicitation technique such as standard gamble or time trade-off (see [20] for an illustration of the use 
of direct utility elicitation to value the EQ-5D in Sweden). Direct utility elicitation is recommended in 
the Swedish guidelines to produce HSUVs. The advantage of direct utility elicitation is that the values 
do not rely upon the accuracy of the described health state as respondents will value their own 
health rather than a description of their own health. There are ethical concerns with asking patients 
to value their own health when they have to consider whether they would rather die than live in 
their current state, which is required in the standard gamble and time trade-off elicitation 
techniques that enable values to be anchored onto the 1-0 full health-dead scale required to 
generate QALY values. In addition patients may have adapted to their poor health and may have 
adjusted their expectations and understanding of what it is like to live in full health, and this can 
impact on the values they provide (potentially providing higher values than the general population 
though we are not aware of any literature providing direct utility values that represent the range of 
possible health states). There are also concerns about the representativeness of patients providing 
direct utility values, as those in very poor health or who are very dissatisfied with their health may 
not provide values [21]. 
 
2.2 Elicitation of preference weights 
A preference weight is a numerical judgement of the desirability of a particular outcome or situation. 
There is a choice of whose values should be used to generate preference weights, and which 
technique should be used to elicit the values (see [17] for an overview). 
 
2.2.1 Preferred population used to elicit preference weights 
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Preference weights for PBMs (or vignettes) can be elicited from the general population, patients, or 
clinicians/experts, where samples of people state how good and bad they think different health 
states are using an elicitation method (see below). Most international agencies (Australia, Canada, 
France, The Netherlands, Spain, England and Wales, Scotland) prefer that the general population is 
used to provide preference weights rather than patients or clinicians/experts. Using preference 
weights elicited from the general population has the advantage that the general population typically 
fund health care via taxation, and they have no vested interest as they do not know which conditions 
they will have in the future. However, they may not take into account adaptation, where patients 
adapt to their condition over time, and may instead provide values that represent what it is initially 
like to be in a poor state which can lead to a lower utility value than is fully representative of all 
patients living in that state. Out of the guidelines included in the review only Sweden and Germany 
recommend that patients are used to elicit preference weights. However, there are concerns with 
the use of preference weights elicited from patients, as (as also outlined above for direct utility 
elicitation) patients may have adapted to their poor health and may have also adjusted their 
expectations and potentially their understanding of what it is like to live in full health, and this can 
impact on the HSUVs they provide.  
 
Guidelines for Australia, France, Germany, The Netherlands, Spain, and England and Wales 
recommend that members of their own country are used to provide preference weights, i.e. the 
value set used to provide the preference weights for the health states must be derived using a 
sample from their own country. For Germany this involves a sample of patients, but for Australia, 
France, the Netherlands, Spain and England and Wales this involves a sample of the general 
population. The recommendation of using own country values is based on evidence that shows that 
value sets differ across different countries, as different populations have different cultures, social 
fabric, family structure, working habits and so forth and this can all impact on the weight given to 
the individual health state. In addition languages differ and this can impact on values, for example 
ďĞŝŶŐ  “ĚĞƉƌĞƐƐĞĚ ?  ?ŶŐůŝƐŚ ? ĂŶĚ ďĞŝŶŐ  “ĚĞƉƌĞƐƐŝĞĨ ?  ?ƵƚĐŚ ? ŵĂǇ ŚĂǀĞ ĚŝĨĨĞƌĞŶƚ ĞŵŽƚŝŽŶĂů
interpretations. Therefore to ensure that the HSUVs used in an economic evaluation represent the 
country population of interest, it is advisable to use the country specific preference weights, i.e. the 
preference-based value set where available. 
 
2.2.2 Preferred elicitation method 
Preference elicitation methods are used to elicit HSUVs for different health states, and methods 
include standard gamble, time trade-off or VAS (visual analogue scale). Preference elicitation 
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methods could be used to value a preference-based measure such as the EQ-5D or a CSPBM, to 
value vignettes, to value ŚĞĂůƚŚ ƐƚĂƚĞƐ ŝŶ ĂŵŽĚĞů ?Žƌ ƚŽǀĂůƵĞ ƚŚĞ ƉĂƚŝĞŶƚƐ ?ŽǁŶ ŚĞĂůƚŚŝ ?Ğ ? ĚŝƌĞĐƚ
utility elicitation. Standard gamble (SG) is a technique where respondents choose between two 
options: a) an impaired health state for certain, and b) a gamble where there is a probability of being 
in full health and a probability of immediate death. The probability of full health is varied until the 
respondent is indifferent between the two options, and the utility value of the impaired health state 
is the probability of full health. Time trade-off (TTO) is a technique where respondents choose 
ďĞƚǁĞĞŶ ĂŶ ŝŵƉĂŝƌĞĚ ŚĞĂůƚŚ ƐƚĂƚĞ ĨŽƌ ? ƐĂǇ ?  ? ? ǇĞĂƌƐ ĂŶĚ ĨƵůů ŚĞĂůƚŚ ĨŽƌ ǆ ǇĞĂƌƐ ǁŚĞƌĞ ǆA? ? ? ? ĂĐŚ
state is followed by immediate death. The number of years in full health is varied until the 
respondent is indifferent between the two options, and the utility value of the impaired health state 
is the number of years in full health. VAS is a technique where a respondent records a mark for an 
impaired health state on, say, a line numbered from 100-0, best health imaginable-worst health 
imaginable, and this mark is the value of the impaired health state. To obtain a value on the 1-0 full 
health-dead scale required for QALYs a mark also needs to be recorded for dead and the value of the 
impaired health state rescaled accordingly. 
 
All guidelines recommend the use of SG or TTO to elicit utility weights (with the exception of 
Germany which does not recommend the inclusion of HSUVs in economic evaluation), and Sweden 
also recommend the use of visual analogue scale VAS. Guidelines for Scotland, Spain and England 
and Wales specify only that the method should be choice-based, which is essentially SG or TTO as 
these are the most common choice-based methods. Typically choice-based methods are 
recommended because they incorporate a notion of sacrifice, where respondents make a sacrifice to 
obtain their choice, and it has been argued that this obtains stated preferences that are more 
representative of actual preferences. For example, in the time trade-off task respondents choose 
whether to sacrifice years of life for better health-related quality of life. This is in contrast to VAS 
where respondents place the health state on a numerical scale, and there is no sacrifice involved. 
Other methods used to generate utility values  such as ranking, discrete choice experiment and best-
worst scaling are not recommended in any of the guidelines, though discrete choice experiment is 
referred to in the guidelines for Australia and the Netherlands.  
 
2.3 Who should complete the questionnaire used to generate HSUVs 
All guidelines either implicitly or explicitly recommend that patients report their own health-related 
quality of life, i.e. complete the questionnaire used to generate HSUVs, reflecting the belief that it is 
people in the condition themselves who have better knowledge and understanding of their own 
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levels of health functioning and symptoms on a daily basis. If patients are unable to report their own 
health-related quality of life, for example due to their level of cognitive functioning, some guidelines 
(France, Spain, England and Wales) explicitly recommend that a proxy may do this on their behalf. 
This proxy could be a family member/primary carer or friend, or more rarely a health care 
professional. 
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Table 2  International recommendations for measuring and valuing HRQoL 
Country Preferred method for 
generating HSUVs 
Alternative to preferred technique Direct 
utility 
assessment 
accepted 
Preferred 
population 
used to 
value 
health 
states 
Preferred 
elicitation 
method 
Patients 
should 
report own 
HRQOL 
Australia Generic PBM: HUI2, 
HUI3, EQ-5D, SF-6D, 
AQoL 
Direct utility assessment, vignettes 
(referred to as scenario-based utility 
valuation), mapping, utilities from the 
literature 
Yes Australian 
general 
population  
SG or TTO Yes (implicit) 
Canada PBM (encouraged, 
implicit this is a generic 
PBM) or direct utility 
assessment 
Willingness to pay Yes General 
population 
SG or TTO Yes (implicit) 
France EQ-5D or HUI3 or any 
other PBM with 
validated French 
preference weights 
CSPBMs and direct valuations of 
descriptions of health states based on a 
generic questionnaire validated for France 
Not 
mentioned 
French 
general  
population 
SG or TTO Yes, if 
inappropriate 
by proxy 
Germany None (note QALYs are 
not the preferred 
technique) 
N/A Not 
mentioned 
German 
patients 
None Not 
mentioned 
The 
Netherlands 
EQ-5D-5L (1) The EQ-5D-3L, (2) Other QALY 
questionnaires such as the SF-6D and the 
HUI, (3) Domain-specific PROMs, such as 
FACT-L and EORTC QLQ-C30, (4) CSPBMs, 
(5) Mapping, (6)  The direct valuation of 
health states in the model, (7) Using 
quality of life weights from the literature 
Not 
mentioned 
Dutch 
general 
population 
SG or TTO Yes 
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Country Preferred method for 
generating HSUVs 
Alternative to preferred technique Direct 
utility 
assessment 
accepted 
Preferred 
population 
used to 
value 
health 
states 
Preferred 
elicitation 
method 
Patients 
should 
report own 
HRQOL 
Spain EQ-5D and SF-6D (from 
SF-36) 
(1) Other generic PBM validated in Spain 
with Spanish weights e.g. HUI3, (2) generic 
PBM not validated in Spain with Spanish 
weights obtained using SG or TTO in 
general population, (3) EQ-5D and SF-6D 
data from other countries using Spanish 
weights, (4) generic PBM data from other 
countries  using non-Spanish weights, (5) 
mapping to generic PBM, preferably EQ-5D 
or SF-6D 
 Not 
mentioned 
Spanish 
general 
population 
Choice-
based 
method 
such as SG 
or TTO 
Yes, if 
unfeasible by 
proxy 
Sweden Direct utility assessment  PBMs such as EQ-5D Yes Patients SG or TTO 
preferred. 
VAS also 
accepted 
Yes (implicit) 
UK: England 
and Wales 
EQ-5D Obtaining utilities from the literature, 
mapping, other measures 
No UK general 
population 
Choice-
based 
method 
Yes or by 
proxy 
UK: Scotland EQ-5D Mapped values, direct utility assessment 
using TTO or SG, utilities from the 
literature 
Yes General 
population 
Choice-
based 
method 
such as SG 
or TTO 
Yes 
Notes: AQoL  W Assessment of Quality of Life; CSPBM  W condition-specific preference-based measure; HSUVs  W health state utility values; HUI  W Health 
Utilities Index;  European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; FACT-L  W Functional Assessment of 
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Cancer Therapy-Lung;  PBM  W preference-based measure; PROM  W Patient-reported outcome measure; SG  W standard gamble; TTO  W time trade-off; VAS  W 
visual analogue scale. 
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3 Overview of international recommendations for data source for obtaining utility data for a 
selection of countries 
Table 3 provides a summary of recommended data sources for HSUVs for each of the international 
guidelines. HSUV evidence for decision analytic models can be sourced from datasets including 
clinical trials, observational studies and the published literature. The guidelines differ in how explicit 
and how detailed the recommendations are regarding the accepted sources of evidence for HSUVs. 
Guidelines for Canada, Sweden and The Netherlands offer little explicit guidance.  
 
3.1 Preferred source for obtaining utility data 
Guidelines for Canada, Spain and the Netherlands do not explicitly state a preferred method for 
retrieving utility data. As discussed above Sweden recommend that HSUVs are direct utility values 
obtained from patients, and this means that existing studies that involved direct utility elicitation 
may be important for providing this information.  
 
Some agencies (Australia, Germany, England and Wales, and Scotland) recommend that HSUVs are 
sourced from clinical trials. However no guidelines explicitly state whether the clinical trial used to 
source utility data is the same trial that should be used to establish clinical effectiveness of the 
treatment, and this is an important issue where more explicit guidelines would be useful. It would 
also be useful to provide a general hierarchy of sources of evidence (such as clinical trial is preferred 
to literature review) and the circumstances under which different sources of evidence are 
appropriate, because the quality of methods used within any given source of evidence can impact 
upon the quality of the evidence. 
 
3.2 Does utility data need to be obtained from own country? 
Guidelines for France state that they prefer utility data (i.e. self-reported health from patients 
scored using an existing value set) obtained from people in their own country (e.g. classification data 
completed in a French sample and scored using French preference weights). This means that HSUVs 
used for the health states in the economic model are obtained from own country data. Own country 
utility data can be provided by using only the data from the own country from a multi-national 
study. All other guidelines do not explicitly recommend this.  
 
3.3 Mapping 
DĂƉƉŝŶŐŝƐĂƚĞĐŚŶŝƋƵĞƚŚĂƚĐĂŶďĞƵƐĞĚƚŽĞƐƚŝŵĂƚĞ,^hsƐƌĞƋƵŝƌĞĚŽƌ ?ƚĂƌŐĞƚ ?HSUVs where they 
are not available in a dataset of interest. Mapping can also be used to model existing data to 
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extrapolate target HSUVs for important clinical end points, and to control for sociodemographic 
variables important for the decision model. Recently published guidelines include guidance 
regarding whether mapping is considered acceptable to estimate HSUVs. Guidelines for Australia, 
Canada, The Netherlands, Scotland and England and Wales state that mapping is acceptable; 
whereas guidelines for France and Germany state that mapping is unacceptable. All countries where 
mapping is acceptable provide further guidance around the use of mapped values, such as when it is 
appropriate or inappropriate (for example in England and Wales it is acceptable to map to EQ-5D if 
EQ-5D data is not available) and the reporting of the generation of mapped values (for example 
England and Wales state that the statistical properties should be fully described, the choice of model 
justified, it should be adequately demonstrated how well the mapping function fits the data and 
sensitivity analyses should be conducted) [22]. 
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Table 3  International recommendations for sources of HSUVs evidence 
Country Preferred source for 
obtaining utility data 
Can utility data 
be obtained 
from clinical 
trials? 
Can utility data be 
obtained from 
observational 
studies? 
Can utility data 
be obtained 
from the 
literature? 
Should utility 
data be 
obtained from 
own country?
#
  
Is mapping an 
acceptable 
method to 
estimate 
HSUVs? 
Australia Clinical trial  Yes Not mentioned Yes (systematic 
search) 
No Yes 
Canada Not explicit Not explicit Yes Yes Not mentioned Yes 
France French data preferred Not explicit Not mentioned Yes Yes No 
Germany Clinical study (note QALYs 
are not the preferred 
technique) 
Yes Not mentioned Not mentioned Not mentioned No 
The 
Netherlands 
Not explicit, implicitly is 
empirical clinical study 
Yes Yes Yes No Yes 
Spain Not mentioned Not mentioned Not mentioned Not mentioned Not mentioned Not mentioned 
Sweden Direct utility values are 
preferred, meaning that the 
use of data from previous 
studies may be the way of 
meeting this criteria 
Not mentioned Yes (implicit) Yes Not mentioned Not mentioned 
UK: England 
and Wales 
Clinical trials Yes Yes Yes (systematic 
review) 
Not mentioned Yes 
UK: Scotland Randomised controlled 
studies of the treatment 
Yes Yes Yes (systematic 
review) 
Not mentioned Yes  
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# 
Note: this is about obtaining utility data (e.g. health self-reported by people with the condition and scored using existing value sets) not about the 
preference weights for scoring the utility data
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4 Overview of international recommendations for use of utility data in the economic model 
for a selection of countries 
The review extracted information on: discount rates for health benefits, baseline or counterfactual 
HSUVs, adjusting/combining HSUVs (e.g. age, gender, comorbidities, etc.), accounting for treatment-
related adverse events, and exploring uncertainty. All guidelines state preferred discount rates 
varying from 3%-5% in the base case and typically 0% and 5% in sensitivity analyses.  However, with 
the exception of capturing uncertainty, they provide few recommendations or guidance relating to 
the other items relating to the use of utility data in the economic model.  While this is not entirely 
unexpected, as they are not technical documents, these factors may have a substantial effect on the 
incremental cost-effectiveness ratio (ICER) [23,24].   
 
All guidelines state that uncertainty should be considered for example using sensitivity analyses, but 
this is regarding uncertainty in general and the recommendations are not specific to HSUVs. The one 
exception is the guideline for England and Wales which specifically mentions that when HSUVs are 
obtained via mapping variance  covariance  matrices  should  be  reported  and  these  should  be  
incorporated  in probabilistic sensitivity analyses.   
 
5 Conclusions and recommendations 
Whilst there are similarities amongst the guidelines included in the review, there is no international 
consensus on guidelines for the collection, generation, source and usage of utility data for health 
technology assessment. International guidelines regarding the generation of utility data are typically 
clear and detailed for the selection of countries assessed regarding the source description of health 
states (for example generic preference-based measure) and who should provide preference-weights 
for these health states (for example general population for own country). Many guidelines specify 
the use of off-the-shelf generic preference-based measures, and some further specify a measure, 
such as the EQ-5D. International guidelines are either unclear or lack detailed guidance regarding the 
collection (for example patient report own health), source (for example clinical trial) and usage (for 
example adjusting for comorbidities) of HSUVs. This creates uncertainty for pharmaceutical 
companies and researchers in trial design, in the sourcing of HSUVs and the construction of 
economic models.  
 
Whilst there are many aspects where countries may legitimately have different preferences, for 
example on their preferred elicitation technique, there are aspects where best practice can be 
defined to inform guidelines. There is a need for transparent and detailed international guidelines on 
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utility data recommendations to provide the best possible evidence to decision-makers. Where this 
is not possible it is recommended that best practice should be used to inform the collection, source 
and usage of HSUVs in economic models, as outlined in the remaining chapters 
[25,26,27,22,28,23,24].  
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